Web12 apr. 2024 · SUZHOU, China, April 12, 2024 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody … Web14 mrt. 2024 · MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of …
Chinese startup MediLink Therapeutics closes $70 M Series B …
Web14 mrt. 2024 · Published on March 15, 2024 MediLink Therapeutics (Suzhou) Co., Ltd., a Shangai, China-based company developing globally competitive conjugated drugs and building a differentiated proprietary ADC... Web14 mrt. 2024 · MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$ 70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of … how was paris killed in romeo and juliet
万博app-球探体育-足球比分_篮球比分_即时比分直播
WebSilverback Therapeutics: SBT6050 (anti-HER2 antibody conjugated to a potent TLR8 agonist), pipeline of ImmunoTAC TM programs: HER2: Series C: Sep 2024: Phase I: $85 million: Silverback Therapeutics: ImmunoTAC TM technology platform: HER2: IPO: Dec 2024: Phase I: $278 million: Suzhou Medilink Therapeutics: Next generation ADCs: … Web10 apr. 2024 · LAS VEGAS, April 10, 2024 (PR Newswire Europe via COMTEX) -- The antibody-drug conjugates market is anticipated to surge as several pharma companies across... how was parent trap made